Search research articles
Contact Us
Filters
Showing results (391-400 of 421) with videos related to
Page
of 43
Sort By:
Blood Cancer Journal
|
January 16, 2016
Karyotype complexity and prognosis in acute myeloid leukemia
F Stölzel, B Mohr, M Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia
Susan O'Brien, Gary Schiller, John Lister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial
Hubert Serve, Utz Krug, Ruth Wagner, et al.
Blood
|
October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Human Mutation
|
September 2, 2011
Large deletions of the KCNV2 gene are common in patients with cone dystrophy with supernormal rod response
Bernd Wissinger, Simone Schaich, Britta Baumann, et al.
Leukemia & Lymphoma
|
January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysis
Jan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial
Christoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2018
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
C Röllig, M Kramer, M Gabrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
Max S Topp, Peter Kufer, Nicola Gökbuget, et al.
The Lancet Regional Health. Europe
|
February 20, 2025
2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies
Michael Sandherr, Jannik Stemler, Enrico Schalk, et al.
Page
of 43
Search research articles
Search
Showing results (391-400 of 421) with videos related to
Sort By:
Page
of 43
Blood Cancer Journal
|
January 16, 2016
Karyotype complexity and prognosis in acute myeloid leukemia
F Stölzel, B Mohr, M Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia
Susan O'Brien, Gary Schiller, John Lister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial
Hubert Serve, Utz Krug, Ruth Wagner, et al.
Blood
|
October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Human Mutation
|
September 2, 2011
Large deletions of the KCNV2 gene are common in patients with cone dystrophy with supernormal rod response
Bernd Wissinger, Simone Schaich, Britta Baumann, et al.
Leukemia & Lymphoma
|
January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysis
Jan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial
Christoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2018
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
C Röllig, M Kramer, M Gabrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
Max S Topp, Peter Kufer, Nicola Gökbuget, et al.
The Lancet Regional Health. Europe
|
February 20, 2025
2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies
Michael Sandherr, Jannik Stemler, Enrico Schalk, et al.
Page
of 43